Dan Marino's MASH diagnosis highlights reversibility of fatty liver disease

Dan Marino, the quarterback who spent seventeen seasons with the Miami Dolphins and rewrote the NFL record books, discovered in 2007 that his liver was storing fat. He was 46 years old, retired from professional football, and had noticed nothing more alarming than a persistent tiredness. A routine checkup revealed the problem: metabolic dysfunction-associated steatohepatitis, or MASH, a condition in which fat accumulates in the liver and triggers inflammation. Doctors delivered both a warning and a reprieve—the damage was reversible if he changed how he lived.

MARINO kept the diagnosis largely private for nearly two decades. Only recently has he begun speaking publicly about it, framing his experience as a case study in how early detection and sustained effort can halt a disease that silently progresses in millions of people. What prompted his checkup was modest: fatigue and a decline in fitness after stepping away from the structured demands of professional athletics. The tests showed fat buildup in his liver. His doctors told him the condition could be turned around through diet, weight management, and consistent exercise. He was now 64, and he had spent nearly seventeen years managing it.

MASH is the more serious stage of a broader liver condition called metabolic dysfunction-associated steatotic liver disease, or MASLD. The distinction matters. MASLD describes any accumulation of excess fat in the liver. MASH occurs when that fat triggers inflammation and begins to damage liver cells. The terminology itself is recent—these conditions were previously called nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, names that reflected what they were not rather than what they were. The newer terms acknowledge that metabolic dysfunction, not alcohol consumption, drives the disease. Left untreated, MASH can progress to fibrosis, scarring of the liver tissue, and eventually cirrhosis or liver failure.

The insidious aspect of MASH is its silence. Many people develop it without knowing. Early symptoms, when they appear at all, are vague: fatigue, weakness, a mild ache in the upper right abdomen where the liver sits. Some people notice swelling in the belly or legs. Marino's experience—mild fatigue alone—is not unusual. As the disease advances, more alarming signs emerge: yellowing of the skin and eyes, fluid accumulation in the abdomen, easy bruising, loss of appetite, unexpected weight loss. By then, significant damage may already have occurred.

The risk factors cluster around metabolic dysfunction. Obesity, particularly excess weight around the midsection, is a primary driver. So are insulin resistance and type-2 diabetes, high cholesterol, high triglycerides, high blood pressure, and the sedentary lifestyle that often accompanies modern work. Marino himself attributed his condition partly to dietary changes after retirement, when the structure and discipline of professional athletics fell away. Age and genetics also play roles—metabolism slows with time, and some people carry genetic variations that increase susceptibility.

MARINO's management strategy became his template for recovery. He adopted a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, and healthy fats. He cut back on processed foods, sugar, refined carbohydrates, and saturated fat. He committed to regular exercise—walking, biking, training with friends. He monitors his liver through ultrasounds and other tests. Even a five to ten percent reduction in body weight, if someone is overweight, can reduce fat in the liver and improve inflammation. Exercise helps reduce liver fat even before significant weight loss occurs.

The medical consensus is clear: when caught early, MASLD and even MASH can be halted or reversed through lifestyle changes. There are currently no universal medications approved for all stages of the disease, though doctors may prescribe treatments for associated conditions like diabetes, high cholesterol, or high blood pressure. Several newer drugs are in trials. For most people, especially those diagnosed early, the path forward is behavioral. Regular checkups matter enormously because symptoms are often absent or mild in the early stages. Blood tests measuring liver enzymes, imaging like ultrasound, and sometimes more advanced evaluations can catch the disease before serious damage takes hold.

MARINO's decision to speak publicly about his diagnosis now serves a dual purpose. It demonstrates that a serious liver condition need not be a death sentence if detected and managed early. It also highlights a gap in awareness—many people at risk for MASH do not know it, do not get checked, and do not know that the condition is reversible. For someone living with the disease, the message is straightforward: early detection and consistent care make a measurable difference. For someone at risk, the message is equally clear: the time to act is before symptoms appear.